Insured patients in the USA would pay up to $200 per month for CBD-based drug Epidiolex under a recent pricing announcement from the maker, UK-based GW Pharmaceuticals.
Epidiolex is the first cannabis-derived pharmaceutical to gain federal approval in the U.S. It was primarily developed for the treatment of two severe forms of epilepsy — Dravet Syndrome and Lennox-Gastaut Syndrome
For the uninsured, Epidiolex will cost about $32,500 per year, or just over $2,700 per month. That’s in line with other prescription drugs used to treat the same afflictions.
“We wanted to make sure we were pricing Epidiolex in such a way where the means to access . . . would be consistent with branded epilepsy drugs these patients already use,” said Justin Grover, GW’s CEO.
Input of insurance companies
The price was determined mainly based on talks with insurance companies, according to Julian Gangolli, GW’s North American President.
